Aluminum (Al) is the third most abundant element in the earth's crust and is omnipresent in
our environment, including our food. However, with normal renal function, oral and enteral …

The incidence of parenteral nutrition‐associated metabolic bone disease is unknown. Initial
reports from the early 1980s suggested that both osteoporosis and osteomalacia were quite …

US6051567A - Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol - Google
Patents US6051567A - Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol …

US6274169B1 - Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol - Google
Patents US6274169B1 - Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol …

US6265392B1 - Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol -
Google Patents US6265392B1 - Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol …

The risk of bone disease in patients receiving long-term parenteral nutrition is significant for
several reasons. Preexisting skeletal disease can occur from malnutrition, mal-absorption …

Parenteral nutrition (PN) is generally given to provide adequate amounts of macronutrients
and micronutrients to allow recovery after injury and illness. Maintenance of the skeleton is …

There is described a therapeutic human albumin having a very low capacity for the
absorption of aluminium, during storage in a glass receptacle, wherein the final composition …

This report was created to assist the Food and Drug Administration (FDA) in their evaluation
of the use of calcium chloride (UNII code: M4I0D6VV5M), which was nominated for use as a …

This report was created to assist the Food and Drug Administration (FDA) in their evaluation
of the use of sodium phosphate, USP (UNII code: SE337SVY37), which was nominated for …